Sun Pharma's Mohali plant receives OAI status from USFDA

09 Nov 2022 Evaluate

Sun Pharmaceutical Industries’ Mohali plant in Punjab has received Official Action Indicated (OAI) classification from United States Food and Drug Administration (USFDA). The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.

The company continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company’s remedial action. Sun Pharma remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally. The plant was inspected in August and had received a form 483 with six observations earlier.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1631.65 -2.75 (-0.17%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×